RISA Labs Secures $11.1 Million to Revolutionize Cancer Care
January 15, 2026, 10:41 am
RISA Labs, a Palo Alto AI innovator, has secured $11.1 million in Series A funding. This capital fuels the nationwide expansion of its AI operating system, BOSS, designed for cancer care. The platform automates critical administrative tasks like prior authorization and benefits verification. It significantly accelerates patient access to vital treatments, addressing long-standing inefficiencies. Cencora Ventures and Optum Ventures co-led the round, supporting RISA's mission to streamline oncology workflows. The technology has already shown remarkable success, slashing insurance denials and boosting approval rates.
RISA Labs, a prominent Palo Alto-based artificial intelligence firm, recently announced a substantial Series A funding round. The company raised $11.1 million. This capital infusion is earmarked for a crucial mission: accelerating patient access to cancer treatments across the United States. The investment underscores a growing recognition of AI's potential to transform healthcare administration.
Cancer care presents unique challenges. Patients often face complex treatment pathways. These paths are frequently hampered by administrative bottlenecks. Obtaining necessary approvals and verifying benefits can delay life-saving therapies. Manual processes dominate these critical steps. They consume valuable staff time and introduce frustrating delays. RISA Labs addresses this pervasive problem directly.
The company developed an AI operating system for oncology. It is called BOSS, an acronym for Business Operating System as a Service. This platform integrates directly with existing hospital electronic medical records (EMR). It also connects to insurance and benefits systems. RISA's AI agents then perform complex, time-consuming tasks. They automate benefits verification. They streamline prior authorization requests. This automation replaces processes traditionally managed by human staff.
The impact is significant. RISA's system demonstrably frees up administrative staff time. Reports indicate an 80% reduction in time spent on these tasks for some clients. This allows healthcare professionals to focus on patient care, not paperwork. The platform also drastically reduces insurance denials. Denials have dropped by up to 40%. First-pass approval rates have soared to 97.8%. These improvements mean more patients receive necessary treatments without delay. Authorizations, once taking days, are now filed within 24 hours.
RISA Labs' technology adapts in real-time. Forms, rules, and interfaces often change across different payer environments and EMR systems. The AI agents respond to these changes seamlessly. This ensures workflow reliability without constant reprogramming. The system is purpose-built for oncology's intricacies. It handles complex payer rules. It navigates multi-drug regimens. It understands disease-specific requirements. This specialized design ensures high efficacy within a demanding medical field.
The BOSS Console serves as the command control panel for institutions utilizing the system. It offers extensive customization capabilities. Users can tailor workflows, routing, and document conventions. Practice-specific rules integrate effortlessly. This makes the system an extension of existing operations. Every AI action is traceable. The platform provides audit-ready records. Leaders gain visibility into system performance. They understand how actions align with compliance and clinical standards. This level of transparency is vital in healthcare.
The funding round saw strong investor participation. Cencora Ventures and Optum Ventures co-led the Series A round. Additional investors included Oncology Ventures, Z21 Ventures, and John Simon's Ventureforgood entity. This diverse group of investors signals confidence in RISA Labs' technology and market strategy. The latest funding follows a $3.5 million seed round. Flipkart co-founder Binny Bansal led that earlier investment in April 2025.
RISA Labs plans to use the new funds to expand its platform rollout nationwide. The system will deploy across cancer clinics. It will reach health systems, specialty pharmacies, and infusion networks. This expansion aims to extend AI-driven workflows across the full continuum of cancer care. The goal remains consistent: speed up access to treatment for every patient.
The founders, Kshitij Jaggi (CEO) and Kumar Shivang (CTO), are IIT Kanpur alumni. They previously built another healthcare startup, Urban Health. Their experience informs RISA Labs' strategic approach. Their vision for oncology focuses on two pillars. First, getting patients on the right therapy faster. Second, deepening disease understanding through data. The BOSS system embodies this dual approach. It streamlines current processes while building a foundation for future data insights.
The market for such solutions is rapidly expanding. Cancer treatments become increasingly specialized and complex. Tools that streamline operations are critical. They enable faster access to essential therapies. RISA Labs is positioned at the forefront of this evolution. Its AI operating system directly addresses a core inefficiency. It delivers tangible benefits to both providers and patients. The investment signals a pivotal moment for AI in healthcare administration. It promises a future where technology removes barriers to timely, effective cancer care.
RISA Labs, a prominent Palo Alto-based artificial intelligence firm, recently announced a substantial Series A funding round. The company raised $11.1 million. This capital infusion is earmarked for a crucial mission: accelerating patient access to cancer treatments across the United States. The investment underscores a growing recognition of AI's potential to transform healthcare administration.
Cancer care presents unique challenges. Patients often face complex treatment pathways. These paths are frequently hampered by administrative bottlenecks. Obtaining necessary approvals and verifying benefits can delay life-saving therapies. Manual processes dominate these critical steps. They consume valuable staff time and introduce frustrating delays. RISA Labs addresses this pervasive problem directly.
The company developed an AI operating system for oncology. It is called BOSS, an acronym for Business Operating System as a Service. This platform integrates directly with existing hospital electronic medical records (EMR). It also connects to insurance and benefits systems. RISA's AI agents then perform complex, time-consuming tasks. They automate benefits verification. They streamline prior authorization requests. This automation replaces processes traditionally managed by human staff.
The impact is significant. RISA's system demonstrably frees up administrative staff time. Reports indicate an 80% reduction in time spent on these tasks for some clients. This allows healthcare professionals to focus on patient care, not paperwork. The platform also drastically reduces insurance denials. Denials have dropped by up to 40%. First-pass approval rates have soared to 97.8%. These improvements mean more patients receive necessary treatments without delay. Authorizations, once taking days, are now filed within 24 hours.
RISA Labs' technology adapts in real-time. Forms, rules, and interfaces often change across different payer environments and EMR systems. The AI agents respond to these changes seamlessly. This ensures workflow reliability without constant reprogramming. The system is purpose-built for oncology's intricacies. It handles complex payer rules. It navigates multi-drug regimens. It understands disease-specific requirements. This specialized design ensures high efficacy within a demanding medical field.
The BOSS Console serves as the command control panel for institutions utilizing the system. It offers extensive customization capabilities. Users can tailor workflows, routing, and document conventions. Practice-specific rules integrate effortlessly. This makes the system an extension of existing operations. Every AI action is traceable. The platform provides audit-ready records. Leaders gain visibility into system performance. They understand how actions align with compliance and clinical standards. This level of transparency is vital in healthcare.
The funding round saw strong investor participation. Cencora Ventures and Optum Ventures co-led the Series A round. Additional investors included Oncology Ventures, Z21 Ventures, and John Simon's Ventureforgood entity. This diverse group of investors signals confidence in RISA Labs' technology and market strategy. The latest funding follows a $3.5 million seed round. Flipkart co-founder Binny Bansal led that earlier investment in April 2025.
RISA Labs plans to use the new funds to expand its platform rollout nationwide. The system will deploy across cancer clinics. It will reach health systems, specialty pharmacies, and infusion networks. This expansion aims to extend AI-driven workflows across the full continuum of cancer care. The goal remains consistent: speed up access to treatment for every patient.
The founders, Kshitij Jaggi (CEO) and Kumar Shivang (CTO), are IIT Kanpur alumni. They previously built another healthcare startup, Urban Health. Their experience informs RISA Labs' strategic approach. Their vision for oncology focuses on two pillars. First, getting patients on the right therapy faster. Second, deepening disease understanding through data. The BOSS system embodies this dual approach. It streamlines current processes while building a foundation for future data insights.
The market for such solutions is rapidly expanding. Cancer treatments become increasingly specialized and complex. Tools that streamline operations are critical. They enable faster access to essential therapies. RISA Labs is positioned at the forefront of this evolution. Its AI operating system directly addresses a core inefficiency. It delivers tangible benefits to both providers and patients. The investment signals a pivotal moment for AI in healthcare administration. It promises a future where technology removes barriers to timely, effective cancer care.